ReviewEuropean cytokine network2026
Re-evaluating cytokine storm syndromes: dysregulated host defense or contextual immune adaptation?
Review in European cytokine network, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cytokine storm syndromes have become a much-invoked concept to describe severe immunopathology in infectious, inflammatory, and iatrogenic diseases, but the concept is poorly defined and often mechanistically imprecise. High levels of systemic cytokines have often been viewed as indicators of immune dysfunction, and based on this notion, therapeutic interventions focused on general cytokine inhibition are proposed. Nevertheless, a growing number of clinical and experimental data dispute the notion that hypercytokinemia is necessarily pathological. The present paper reconsiders cytokine storm syndromes in the light of an evolutionary, systems-immunology model, and suggests that most cytokine amplification conditions are context-specific host defence programmes, however, not uniform maladaptations of immune regulation. Its major objective is to redefine the cytokine storm syndromes, which are no longer understood as a single, uniformly pathological situation, but as a spectrum of context-specific immune programmes. The paper reviews disease-specific phenotypes of cytokine storms in viral infections, bacterial sepsis, autoimmune diseases, and immune-based therapies, noting considerable variability in cytokine composition, kinetics of production, cytokine-producing cell frequency, and localization in tissues. It also explains how the temporal dynamics, host-specific conditions, and failure of counter-regulatory mechanisms define the difference between cytokine amplification as an adaptation or as a pathological condition. In addition, it considers the clinical consequences of such a refined framework and argues that exploring precision strategies need to consider immune context, disease stage, and signalling thresholds, as opposed to a general use of blocking cytokines. In conclusion, this review attempts to draw a line between adaptive cytokine amplification and maladaptive immunopathology by integrating the insights gained in evolutionary biology and systems immunology.
Indexed as
Identifiers
42086342What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.